Elie Lily and Partners today
Elie Lily and Partners
As of 09/18/2025 03:59 pm
- 52 weeks
- 623.78 dollars
▼
939.86 dollars
- Profit
- 0.79 %
- P/E ratio.
- 49.86
- The target price
- 939.61 dollars
Elie Lily and Partners New York: Li It has been one of the best performances outside the improved and improved stocks over the past 12 months. Company The pioneer in the GLP-1 marketWhich converts the type 2 diabetes management and obesity market.
LLY shares rise 10 % Last month, on the news indicating that the US Food and Drug Administration (FDA) indicated that it might quickly follow the orally GLP-1 candidate.
Many users do not like or do not want to deal with continuous needle injections. This development can redefine the dynamics of access and cost in space-and the expansion of the GLP-1 market significantly.
GLP-1 orally: Change the game for patients and motives
Elie Lily’s expectations and company stock company today
939.61 dollars
23.17 % upModerate purchase
Based on 24 analyst classification
| The current price | 762.84 dollars |
|---|---|
| High expectations | $ 1,190.00 |
| Average expectations | 939.61 dollars |
| Low expectations | 700.00 dollars |
Elie Lily and the company’s forecasts details
Since the emergence of the GLP-1 market, patients and investors have wondered about the feasibility of oral solution. Lilly is not the only company to test the GLP-1 solution by mouth, but it appears to be farther as far, as it becomes clear from the recent news that the FDA (FDA) may follow the drug under a recently launched review process.
Although he was not guaranteed, many analysts believe that there are two reasons for existence.
The first reason is The cost and easy access. When used specifically for weight loss (unlike type 2 diabetes treatment), GLP-1 medications are rarely covered with insurance at the present time. This is a great burden for the cost for weight loss drugs. If oral delivery can reduce costs, insurance companies may be more open to coverage.
The second reason is a night strategy 27 billion dollars investment in the United States. In the past, the Trump administration has criticized the vital pharmaceutical market for its small manufacturing program in the United States. Lily changes this with the obligation of $ 5 billion Building a manufacturing factory in Virginia To increase local production for both oncology medications and oral GLP-1 candidate. These are the first four new facilities that Lily plan to build in the United States.
This step deals with fears of gaps in the pharmaceutical supply chain, especially those that arose during the Trump administration. The cold also reduces the risk of customs tariffs and may appeal to the organizers as a sign of national alignment.
Why LLY is better as a long -term comment
LLY shares rose approximately 400 % In the past five years. However, many merchants described the stocks “dead money” during the year and a half last year. They have reasons to stay away.
For beginners, there is an increasing competition in the GLP-1 market. Novo Nordisk is still a basic night competitor, but Lili still has an advantage in the speed of the development of the drug and the manufacturing scale.
In addition, the uncertainty about the insurance coverage of obesity treatments may weigh on profits in the short term, but the long -term story remains intact.
Elie Lily and profit distribution payments company
- Profit
- 0.79 %
- Annual profit distributions
- 6.00 dollars
- Record of profit distributions
- 11 years old
- The percentage of profit distribution
- 39.22 %
- Pay the last profits
- September 10
Date of profit distribution
However, there are also many reasons for holding stocks as a long -term investment.
Beyond the GLP-1S, Lilly’s Oncology and Lilly’s Oncology-Edibody-DRUG Conjugate are more growth. This long-term catalyst can be lost in the justified enthusiasm on the company’s GLP-1 medications. The focus on American manufacturing is a strategic trench that diversifies the revenue base and reduces political and logistical risks.
From a basic perspective, LLY shares are traded with 32X front profits only. This is costly compared to other large pharmacy companies, but it is a good value compared to the historic Lilly average and its dominance in the GLP-1.
In addition, the company offers dividends with attractive payments of $ 6 per share annually. Although it is not an impressive return at about 0.79 %, profit distributions have increased for 11 consecutive years and have a sustainable payment rate of about 39 %.
Before you think about Eli Lilly and Company, you will want to hear it.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before wiping the broader market … and Eli Lilly and Company were not in the list.
While Eli Lilly and Company currently has a moderate purchase classification between analysts, higher -rated analysts believe that these five stocks are better.
Show the five stocks here
Opening the immortal value of gold with the exclusive gold prediction report 2025. Explore why gold remains the final investment to protect wealth against inflation, economic transformations and global doubts. Whether you are planning for future generations or seeking a reliable origin in troubled times, this report is your primary guide to make enlightened decisions.
